HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

Clearmind Medicine Inc.

Contributing Author

Recent Articles by Clearmind Medicine Inc.

Jul-03
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center CMND GlobeNewswire
Jun-30
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder CMND GlobeNewswire
Jun-27
Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market CMND GlobeNewswire
Jun-25
Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment CMND GlobeNewswire
Jun-24
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics CMND GlobeNewswire
Jun-23
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder CMND GlobeNewswire
Jun-12
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics CMND GlobeNewswire
Jun-05
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment CMND GlobeNewswire
May-20
Clearmind Medicine to Host Live Webinar "Gazing Through the Crystal Ball" Featuring Leading Psychedelic Experts CMND GlobeNewswire
May-12
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction CMND GlobeNewswire
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite